Celine Roger-Dalbert is the Vice President of Research & Development, in Molecular, Microbiology and Point of Care Diagnostics, for Becton Dickinson. She is responsible of all new product development activities including molecular assays, rapid immunoassays, cytology and traditional microbiology products for respiratory and enteric infections, hospital acquired infections, septicemia, sexually transmitted infections and women’s health. In her 12 years at BD, she has been involved in more than 20 new product launches, including new or innovative technologies and contributing to delivering differentiated solutions improving clinical outcomes. She is the recipient of two Wesley J. Howe awards for Invention of New technology and contribution to product success. She currently oversees the development of innovative diagnostic development programs for SARS-Coronavirus-2, including molecular assays and immuno-assays.
Prior to joining BD, Celine has held different management roles for bioMerieux, in their Research & Development, Microbiology division. During those 10 years, she was responsible of the development of chromogenic media for infectious diseases and hospital acquired infections. Some of these culture media were new applications in this field like detection of Extended-Spectrum -Lactamase resistance Gram Negative bacteria. She also led external collaborations with academic teams to develop new chromogenic biochemical substrates for micro-organisms identification and susceptibility testing. She was also involved on the development of two microbiology platforms for clinical identification and susceptibility testing of microorganisms and for pathogens quantitation in food testing.
Celine earned an Engineer degree in Biotechnology from the Catholic University in Lyon, France and a Master from the University Claude Bernard in Lyon, France.
Celine is the co-inventor of more than 15 patent applications. She has worked in France, Canada and is currently working in the United States.